Bioinnovo has participated in 2021 ISV Annual Virtual Congress by sharing experiences in the development of innovative veterinary vaccines to fight against several diseases, and by introducing the successful case of Vedevax Block, the first subunit recombinant vaccine in the world that has been approved to be used against the bovine viral diarrhea virus (BVDV)
The 2021 ISV Annual Virtual Congress, an event organized by the International Society for Vaccines (ISV), was held from September 13 to September 15. The director of the platform INCUINTA, the Veterinary and Agricultural Sciences Research Center (CICVyA), and the National Institute of Agricultural Technology (INTA); Principal Investigator of the National Scientific and Technical Research Council (CONICET); and Bioinnovo SA Scientific Director, Andrés Wigdorovitz, participated in this event as a guest speaker and held two conferences. One of them addressed Vedevax Block development and field results, while the other addressed a new vaccine against the foot and mouth disease virus, which was developed together with Biogénesis Bagó.
In his presentation, Wigdorovitz shared the current working experience of Bioinnovo’s team in the development of targeted vaccines, where the first product of the platform is Vedevax Block, and in virus-like particles for the foot and mouth disease virus.
During the conference, the successful case of Vedevax Block was presented, which is the first subunit recombinant vaccine in the world that has been approved to be used against the bovine viral diarrhea virus (BVDV), a disease that causes great economic losses in bovine herds globally. It is a Bioinnovo’s development and it is produced with a different approach from the one used with traditional vaccines: this vaccine combines the glycoprotein E2 of the virus with the APCH antibody, which has affinity for the immune system. “This mechanism highly increases its efficacy”, he said.
The trial results in over 7,000 dairy and breeding cows at different sites and with different sanitary conditions show that Vedevax Block is highly immunogenic in countryside conditions. This makes it a useful tool to reduce the productive and reproductive losses related to bovine viral diarrhea virus infection.
“Vedevax Block is an example of leadership as a result of a series of successful cooperation experiences between INTA and Vetanco,” Wigdorovitz said. He also mentioned that INCUINTA has the facilities and the method to develop and produce effective, new-generation veterinary vaccines at a pilot scale.
About the Event
The Congress included prerecorded and live sessions in different focus areas, starting with two main speeches and an introduction of the new grantees from the International Society for Vaccines, which were followed by several scientific sessions.
It is the greatest non-commercial, scientific gathering in the world, which covers every aspect of vaccine policy and public health, research and development of vaccines and immunotherapies for human and zoonotic diseases.
The conference is a useful platform to join people from every area of the global vaccine community with the aim of learning about the latest improvements in the field, discussing challenges and opportunities, and networking. The ISV has organized conferences around the world, including the USA, France, and Belgium.
It is worth noting that the International Society for Vaccines (ISV) encourages the development and use of vaccines/immunizations to prevent and control infectious and non-infectious diseases in humans and animals. It also supports the professional development of scientists in the immunization field, including apprentices.
For more information on the Congress, visit: https://isvannualvirtualcongress.vfairs.com/